All In Biotech

Free tool

FAERS Monitor: Voquezna

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218710 or its brand name (Voquezna, Vonoprazan Fumarate). Reports on generic versions are filed under their own applications.

Reports

8,132

Serious

5,240

64% of reports

Hospitalization

3,206

Death reported

1,069

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea526
  • off label use520
  • nausea485
  • drug ineffective457
  • gastrooesophageal reflux disease322
  • malaise317
  • decreased appetite272
  • headache271
  • pyrexia253
  • abdominal pain upper251
  • vomiting242
  • product dose omission issue232
  • illness216
  • dizziness214
  • dyspnoea214

Reports by year received

View as table
YearReports
20101
20111
20141
20152
201617
201741
201890
2019119
2020166
2021426
2022807
2023880
20241,448
20252,182
20261,951

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,027 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
gastrooesophageal reflux diseaseSignal32210.49.32,720
illnessSignal2165.44.8779
abdominal pain upperSignal2513.22.8371
decreased appetiteSignal2723.02.7372
diarrhoeaSignal5262.11.9315
product dose omission issueSignal2322.01.8124
pyrexia2531.91.7107
malaise3171.91.7130
nausea4851.61.5108
off label use5201.51.4101
vomiting2421.31.220
headache2711.11.03
dizziness2141.11.02
dyspnoea2141.00.90
drug ineffective4570.90.86

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.